UK biotech Autifony has signed an exclusive licensing deal with Jazz Pharmaceuticals, giving the Ireland-headquartered drugmaker global rights to a pair of ion channel targets associated with neurological disorders.
The Stevenage-based company – which was founded by former GSK scientists in 2011 – is getting an undisclosed upfront payment from Jazz in return for the rights and is in line for milestone payments that could be worth up to $770.5 million plus royalties on future net sales.
